Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2013, with the report dated December 11, 2013. The filing serves as a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance announcement rather than a financial results report.
Material Changes
The filing announces a change in the composition of the Board Committee:
- Lynn Elsenhans, a Non-Executive Director, has been appointed as a member of the Audit & Risk Committee.
- The appointment is effective as of January 1, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the effective date of Lynn Elsenhans' appointment to the Audit & Risk Committee (January 1, 2014).
- Confirm the current composition of the Audit & Risk Committee following this appointment.
- Note that this filing contains no financial performance data for the period ending December 2013.